Overview
The BD Phoenix™ M50 instrument provides clinicians with accurate and timely identification and susceptibility results to help guide their therapy and patient management decisions.
Features and Benefits
Trusted performance: The BD Phoenix™ system provides on-panel doubling dilutions and built-in detection resistance, including CPO, MRSA, mecA, VRSA, VRE, ESBL, HLAR, and iMLSb*.
Ease of use: The system requires no reagent additions post inoculation and few supplemental tests for final result determination, while utilizing leak-resistant, room-temperature panel storage.
Scalability: The instrument is compact and stackable, allowing for increased testing volumes by doubling capacity within the same footprint.
Advanced data management: The BD EpiCenter™ data management system interfaces with the BD Phoenix™ M50 and provides intuitive, on-demand antibiogram generation and flexible reporting options.
Appplications
- The BD Phoenix™ M50 system instrument offers identification-only panels and combination ID/AST panels, using 51 wells for identification substrates.
- The system can provide rapid identification of most clinically significant Gram-negative and Gram- positive bacteria, as well as yeast.
- The BD Phoenix™ M50 system offers 85 wells for antimicrobial dilutions on standard AST-only panels and combination ID/AST panels, and 136 wells on the BD Phoenix™ Emerge™ panel.
- The instrument can provide rapid susceptibility results for most clinically significant Gram-negative and Gram-positive bacteria.
- The BD Phoenix™ M50 system panels test for several resistance markers*such as**:
- Gram-positive bacteria
- HLAR—High Level Aminoglycoside Resistant Enterococcus
- iMLSb—Inducible Clindamycin Resistance
- MRSA—based on Oxacillin Interpretation with Staphylococcus species
- mecA – detection of mecA-medicated resistance in Staphylococcus aureus
- BL- Staphylococcus ß-Lactamase (Nitrocefin based test)
- VRSA—Vancomycin-Resistant Staphylococcus Aureus
- VRE—based on Vancomycin interpretation
- Gram-negative bacteria
- CPO—Carbapenemase Producing Organism
- ESBL—offered on Gram-negative panels and requires no additional disc diffusion or E-Test confirmation.
- The BD Phoenix™ CPO detect test, available on certain BD Phoenix™ Gram-negative panels, provides information, including Ambler classification, to help guide clinicians in their treatment decisions.
- This test is available in two-panel configurations that allow microbiology labs to test for CPOs as part of routine susceptibility testing on BD Phoenix™ panels:
- 2-well configuration—provides detection of Carbapenemase-producing organisms in Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii
- 9-well configuration—provides detection of carbapenemase-producing organisms and Ambler classification (A, B or D) in Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii
- The BD Phoenix™ CPO detect test is currently the only phenotypic test on an automated AST system that provides CPO detection and Ambler classification.
- On average, the BD Phoenix™ CPO detect test detects and classifies CPOs from isolated colonies within 6 to 11 hours.**
